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Abstract 
Differentiation of human mesenchymal stem cells (hMSCs) requires the rewiring 
of energy metabolism. Herein, we demonstrate that the ATPase Inhibitory Factor 1 
(IF1) is expressed in hMSCs and in prostate and colon stem cells but is not expressed in 
the differentiated cells. IF1 inhibits oxidative phosphorylation and regulates the activity 
of aerobic glycolysis in hMSCs. Silencing of IF1 in hMSCs mimics the metabolic 
changes observed in osteocytes and accelerates cellular differentiation. Activation of 
IF1 degradation acts as the switch that regulates energy metabolism during 
differentiation. We conclude that IF1 is a stemness marker important for maintaining 
the quiescence state.  
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Introduction 
A master regulator of energy metabolism in aerobic differentiated cells is the 
mitochondrial H+-ATP synthase, the engine of oxidative phosphorylation (OXPHOS) 
that catalyzes the synthesis of ATP using as driving force the proton gradient generated 
by the respiratory chain. The ATPase Inhibitory Factor 1 (IF1) [1] is the physiological 
inhibitor of the H+-ATP synthase that is highly overexpressed in mitochondria of cancer 
cells [2]. The overexpression of IF1 results in the inhibition of the ATP synthetic 
activity of the enzyme, the switch to an increased aerobic glycolysis [2] and the ROS-
mediated signaling of several features of the oncogenic phenotype [3]. These findings 
supported a role for IF1 as a master regulator of energy metabolism and retrograde 
nuclear signaling in cancer. 
Adult human mesenchymal stem cells (hMSCs) are characterized by their multi-
lineage differentiation potential (pluripotency) and their self-renewal capacity [4]. 
Recently, the study of energy metabolism of stem cells has received attention because of 
its implication in nuclear reprogramming. Undifferentiated pluripotent stem cells have a 
low activity of mitochondrial OXPHOS and preferentially utilize aerobic glycolysis as a 
major source of energy supply [4]. In contrast, differentiated cells depend more heavily 
on OXPHOS [5, 6]. Interestingly, stemness factor-mediated nuclear reprogramming of 
somatic cells induces the downregulation of OXPHOS concurrently with the activation 
of glycolysis [7]. However, the mechanism and signaling molecule that gears the stem 
cell decision to change its energy metabolism and hence to onset proliferation or 
differentiation programs are unknown.  
Here we demonstrate that the enhanced bioenergetic activity of mitochondria 
upon osteogenic induction is not supported by proliferation of the organelles but by the 
bioenergetic differentiation of pre-existing mitochondria. We show that IF1 is expressed 
 4
in hMSCs and in stem cell niches of CD44 positive cells of the human prostate and 
colon but is not expressed in differentiated osteocytes. Remarkably, IF1 promotes 
aerobic glycolysis in hMSCs and its expression is stringently regulated by degradation 
during osteogenic induction. Our findings support a functional role for IF1 in the 
regulation of stem cell fate decisions.  
 
 
 
Results 
Onset of OXPHOS upon osteogenic differentiation. Osteogenesis from 
hMSCs promoted a large change in cellular morphology (Fig. 1A) with concurrent 
upregulation of the osteogenic marker osteopontin (Fig. 1B) and down-regulation of the 
stem cell marker CD44 (Fig. 1B). Hence, the osteopontin/CD44 ratio, an index of 
osteogenic differentiation, was significantly increased in osteocytes when compared to 
hMSCs (Fig. 1B).  
Basal rates of aerobic glycolysis were not significantly different between hMSCs 
and osteocytes (Fig. 1C). Inhibition of OXPHOS with oligomycin (OL) did not affect 
the rates of aerobic glycolysis in hMSCs (Fig. 1C) but promoted an increase in 
glycolysis in osteocytes (Fig. 1C). Consistently, osteocytes showed a significant 
increase in basal, oligomycin sensitive (OSR) and maximum uncoupled (MRR) 
respiratory rates (Fig. 1D). Basal cellular ATP concentrations were not significantly 
different between hMSCs and osteocytes (Fig. 1E). However, OL only promoted a 
significant decrease in ATP content in osteocytes (Fig. 1E). The drop in ATP levels in 
response to OL treatment in osteocytes could not be attributed to an enhanced cell death 
(Fig. S1) but as a result of a higher dependence of this cellular type on OXPHOS.  
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Osteogenic induction triggers mitochondrial differentiation. Cellular 
differentiation triggered a significant increase in the expression of NADH subunit 9 
from complex I, succinate dehydrogenase B from complex II, core 2 from complex III, 
cytochrome c oxidase subunits I and II from complex IV and the α- and β-F1-ATPase 
subunits of the H+-ATP synthase from complex V of OXPHOS (Fig. 2A and Fig. S2A). 
A concurrent decrease in the expression of the glycolytic proteins glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), pyruvate kinase isoform M2 (PK-M2) and lactate 
dehydrogenase A (LDHA) was observed (Fig. 2A and Fig. S2A). Hence, the overall 
mitochondrial capacity of the cell (β-F1-ATPase/GAPDH ratio) [8] (see Supplemental 
Information) was significantly augmented in osteocytes (Fig. S2A). Other mitochondrial 
proteins such as NADH Fe-S protein 3 (NDUFS3) from complex I, cytochome oxidase 
subunit IV from complex IV, hydroxyacyl-CoA dehydrogenase (HADHA) of β-
oxidation, porin (VDAC) and the structural mitochondrial protein Hsp60 revealed no 
relevant changes during osteogenic induction (Fig. 2A and Fig. S2A). Analysis of 
OXPHOS complexes in blue native gels revealed no relevant differences in their 
assembly between hMSCs and osteocytes (Fig. S2B) supporting that their assembly is 
not limiting OXPHOS in hMSCs. 
In contrast with recent findings [6] we observed that osteogenic induction 
occurred in the absence of relevant changes in mitochondrial DNA (mtDNA) copy 
number (Fig. 2B) as well as in mitochondrial mass as assessed by the cardiolipin 
content of the cell (Fig. 2C). Analysis of mitochondrial morphology and abundance 
using MitoTracker Red revealed large differences in organelle shape (Fig. 2D) and the 
absence of differences in mitochondrial content (histogram in Fig. 2D). Mitochondria in 
hMSCs were predominantly punctiform whereas the thread-like morphology was more 
abundant in osteocytes (Fig. 2D), in agreement with previous findings in pluripotent 
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stem cells [9]. High-resolution electron microscopy further confirmed no significant 
differences in the number of mitochondria per cell section between osteocytes and 
hMSCs (Fig. 2E). However, hMSCs contained a high percentage of mitochondria with 
abnormal structure when compared to mitochondria in osteocytes (Fig. 2E). These 
results indicate that osteogenic induction promotes the bioenergetic differentiation of 
mitochondria rather than organelle proliferation as supported by the increase in the β-
F1-ATPase/Hsp60 ratio [8] (see Supplemental Information) observed in osteocytes 
when compared to hMSCs (Fig. 2F). 
We observed no relevant differences in the expression of β-F1-ATPase mRNA 
between hMSCs and osteocytes (Fig. S3A) suggesting that the expression of β-F1-
ATPase (Fig. 2A) is controlled at the level of mRNA translation during differentiation, 
what is in agreement with similar findings in development and in oncogenesis [10]. 
miR-127-5p targets the 3´UTR of β-F1-ATPase mRNA and inhibits its translation [11]. 
However, both hMSCs and osteocytes do not express significant levels of miR-127-5p 
(Fig. S3B) indicating that it is not involved in repressing the bioenergetic differentiation 
of mitochondria in hMSCs.  
IF1 regulates energy metabolism of stem cells. Western blot analysis revealed 
that osteocytes do not express IF1 when compared to hMSCs (Fig. 3A). siRNA-
mediated silencing of IF1 in hMSCs resulted in a significant reduction of the rates of 
aerobic glycolysis (Fig. 3B). In this situation OL treatment promoted a significant 
increase in lactate production (Fig. 3B). Consistently, downregulation of IF1 in hMSCs 
promoted an increase in the activity of the mitochondrial H+-ATP synthase (Fig. 3C). 
Although basal cellular ATP concentrations were not affected by IF1 downregulation 
(Fig. 3D), a significant drop in cellular ATP content occurred in the presence of OL in 
IF1-silenced hMSCs (Fig. 3D). These results suggest that IF1 is part of the switch that 
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controls energy metabolism upon osteogenic induction of hMSCs (Fig. 1). The 
regulated expression of IF1 does not affect the proliferation rate of hMSCs (Fig. S4) in 
contrast to data obtained in colon cancer cells [3] suggesting a cell-type specific 
variability in nuclear responses to IF1 signaling.  
Regulation of IF1 expression in stem cells. hMSCs and osteocytes revealed no 
relevant differences in the cellular content of IF1 mRNA (Fig. 3E). Twenty-four hour-
treatment of hMSCs and osteocytes with AEBSF (a serine protease inhibitor) promoted 
a large accumulation of IF1 in both cellular types (Fig. 3F). However, the accumulation 
of IF1 in AEBSF-treated osteocytes exceeded by 3-fold the accumulation observed in 
hMSCs, suggesting that normal differentiated cells degrade IF1 at much faster rate than 
hMSCs. A siRNA-based screen aimed at the identification of the protease involved in 
the degradation of IF1 in hMSCs (Fig. S5A) and HCT116 colon cancer cells (Fig. S5B) 
failed to provide a candidate responsible for the degradation of IF1 despite evidence of 
partial silencing of the seven proteases tested (Fig. S5). Remarkably, whereas treatment 
of hMSCs with AEBSF did not induce significant changes in the rates of aerobic 
glycolysis (Fig. 3G), the same treatment in osteocytes triggered a large increase in the 
glycolytic flux (Fig. 3G), comparable to that induced by treatment with OL (Fig. 3G). 
Moreover, silencing of IF1 accelerated the rate of differentiation as revealed by the 
osteopontin/CD44 ratio after 12 days of osteogenic induction (Fig. 3H) suggesting a 
role for IF1 in signaling the repression of cellular differentiation.  
IF1 is a marker of stem cells. Immunohistochemistry of IF1 revealed that it is 
expressed in basal epithelial cells of the prostate (Fig. 4A) and in the Lieberkühn crypts 
of the colon (Fig. 4A). A high expression of IF1 was also observed in prostate and colon 
carcinomas (Fig. 4A). Double-immunofluorescence microscopy analysis for CD44 and 
IF1 in human prostate and colon showed the colocalization of both markers in basal 
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epithelial cells and Lieberkühn crypts, respectively (Fig. 4B), which are the sites where 
stem cells are located in these tissues [12, 13].  
 
Discussion 
Metabolic reprogramming during cellular differentiation [4-6] or in the 
dedifferentiation of somatic cells into iPSC [7] or into cancer cells [3] is well 
established. Here we show that upon osteogenic differentiation of hMSCs there is an 
up-regulation of proteins of complex I, II, III, IV and V of OXPHOS. These changes 
result in an increase in the activity of the respiratory chain and of the H+-ATP synthase 
and a higher dependence of osteocytes on OXPHOS to provide the ATP needed to 
sustain cellular specialization. Despite the enhancement of OXPHOS and the partial 
down-regulation of the cellular content of glycolytic enzymes in osteocytes, the 
differentiated cells still show similar rates of glycolysis as hMSCs indicating that the 
higher energy requirements of osteocytes cannot be covered by OXPHOS alone. 
Moreover, the maintenance of the glycolytic flux despite the diminished expression of 
glycolytic enzymes in osteocytes highlights the relevance of allosteric regulation of this 
metabolic pathway.  
The mitochondrial phenotype of a given cell is the result of cell-type specific 
programs that are regulated at both the transcriptional [14] and post-transcriptional [10] 
levels. Transcriptional programs usually result in the onset of mitochondrial 
proliferation [14] whereas post-transcriptional ones promote the rapid bioenergetic 
differentiation of the organelle in response to changing physiological cues (for review 
see [10]). Our findings indicate that the enhanced activity of OXPHOS in osteocytes is 
not supported by an enhanced mitochondrial proliferation but by the bioenergetic 
differentiation of pre-existing stem cell mitochondria in agreement with findings upon 
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pluripotent stem cell differentiation [9, 15]. Consistently, the bioenergetic 
accomplishment of mitochondria during osteogenesis also seems to be regulated at post-
transcriptional level [10]. 
Rewiring of energy metabolism to aerobic glycolysis has been shown to foster 
nuclear reprogramming both during oncogenesis [16] and in dedifferentiation to iPSC 
[7]. However, the molecule that orchestrates the metabolic switch during stem cell 
differentiation remains elusive. Here, we show that IF1 regulates energy metabolism of 
hMSCs by inhibiting the activity of OXPHOS and promoting aerobic glycolysis 
reproducing the effect of OL in cellular metabolism [2]. Kinetic evidence indicates that 
IF1 inhibits the ATP hydrolase activity of the H+-ATP synthase [1]. However, it is 
likely that binding of IF1 to the H+-ATP synthase also depends on the mass-action ratio 
and hence when IF1 is expressed, as it is the situation in hMSCs, it can also inhibit the 
synthase activity of the enzyme. Indeed, silencing of IF1 in hMSCs resulted in a drop in 
glycolysis and a concurrent increase in ATP synthase activity. Conversely, its 
overexpression in different cell types has been shown to increase glycolysis and to 
inhibit the ATP synthase activity, mimicking the metabolic effects triggered by the ATP 
synthase inhibitor OL [2, 3]. Moreover, we document the expression of IF1 in hMSCs 
as well as in human prostate and colon stem cells but not in osteocytes and other 
differentiated cells. Remarkably, disappearance of IF1 seems to be a prerequisite to 
facilitate the metabolic switch that accompanies cellular differentiation, emphasizing the 
prominent role that IF1 might play in the maintenance of stemness. However, other 
mechanisms might also operate since it has been reported that human pluripotent stem 
cells have a low content of IF1 and their differentiation is triggered by repression of 
UCP2 [9].  
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Recent findings have stressed the relevance of post-translational modification of 
pluripotency-associated transcription factors to simultaneously maintain pluripotency or 
induce lineage-specific differentiation (for review see [17]). The results in this report 
add on the same idea by stressing the relevance of the degradation of IF1 in maintaining 
energy metabolism of the undifferentiated state of stem cells. The accumulation of IF1 
in response to the inhibitor AEBSF indicates that the protein is degraded by a 
mitochondrial serine-protease. The enhanced degradation of IF1 in osteocytes might 
thus result from the activation of any of these proteases as a surrogate process of the 
nuclear reprogramming that renders ongoing the differentiated state and/or because IF1 
is experiencing a post-translational modification that makes it more susceptible to 
degradation. Our screening for the putative protease involved indicates that degradation 
of IF1 is more complex than originally anticipated and might involve an unexplored 
pathway for the degradation of mitochondrial proteins.   
Cancer and stem cells display large phenotypic analogies regarding the 
molecular and functional activities of the proteins involved in glycolysis and in 
mitochondrial OXPHOS (Fig. 4C). The expression of IF1 represents an additional 
phenotypic trait in common (Fig. 4C). Deciphering the nuclear responses to the 
presence or absence of IF1 will certainly contribute to understand stem cell fate 
decisions. Overall, we show that IF1 is a stem cell marker that regulates energy 
metabolism of hMSCs. The regulated degradation of IF1 hinders self-renewal of stem 
cells to favor differentiation.  
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Methods 
Culture of hMSC. hMSCs were obtained from Lonza and cultured according to 
manufacturer’s instructions, for additional details see Supporting Information.  
Determination of aerobic glycolysis and oxygen consumption rates. The rates 
of aerobic glycolysis were determined by the enzymatic determination of lactate in the 
medium in the absence or presence of 6 μM OL [18]. The oxygen consumption rates 
were determined in a XF24 Extracellular Flux Analyzer (Seahorse Biosciences) [2].  
Determination of ATP. Cells were incubated for 1h in the presence or absence 
of 6µM OL and cellular ATP concentrations were determined using the ATP 
Bioluminiscence Assay Kit CLS II (Roche). 
Western blot analysis. Cellular lysates were processed for blotting as indicated 
[2]. Details of the antibodies used are provided in Supporting Information.  
Determination of mtDNA copy number. After cellular DNA extraction the 
quantification of mtDNA (mtDNA/nDNA) was performed by qPCR using the 
LightCycler® 2.0 Real-Time PCR System as described [19]. 
Electron microscopy. For ultrastructural studies, hMSC and osteocytes were 
fixed with 2% glutaraldehyde in 0.1M Sörensen phosphate buffer pH 7.4 and processed 
for electron microscopy as detailed elsewhere [18].  
Fluorescence microscopy. Cells were incubated for 45 min with 500 nM 
Mitotracker Red FM (Invitrogen) followed by staining with Hoechst (1 mg/ml) for 10 
min at 37º C. Cellular fluorescence was analyzed in a Axiovert 200 (Zeiss) microscope 
using a ccd camera. The red fluorescence intensity of the cells was calculated using 
Image J. 
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Statistical analysis. Statistical analyses were performed using a two-tailed 
Student’s t test. The results shown are the means±S.E.M. A p<0.05 was considered 
statistically significant. 
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Figure legends 
Figure 1. Metabolic reprogramming of stem cells upon osteogenic differentiation. 
hMSCs were grown in the osteogenic induction media to promote differentiation. (A) 
Representative images of undifferentiated stem cells (hMSCs) and osteocytes. (B) 
Western blots of the expression of CD44, osteopontin and tubulin in two different 
preparations of hMSCs and osteocytes (Ost.). The histograms show the calculated 
osteopontin/CD44 ratio. Bars are the mean ± S.E.M of four different samples. *, p<0.05 
when compared to hMSCs. (C) hMSCs and osteocytes were processed for the 
determination of the rates of aerobic glycolysis in the absence (-) or presence (+) of 
6μM oligomycin (OL). Bars are the mean ± S.E.M. of 6-10 independent determinations. 
*, p<0.05 when compared to OL-untreated cells. (D) The rates of basal respiration were 
determined in hMSCs and osteocytes. OL-sensitive respiration (OSR) and maximum 
respiratory rates (MRR) were also measured after the addition of 6μM OL and 0.75 mM 
DNP, respectively. Bars represent the mean ± S.E.M. of three independent experiments. 
*, p<0.05 when compared to hMSCs. (E) Cellular ATP concentrations were determined 
in the absence (-) or presence (+) of 6μM OL. Bars are the mean ± S.E.M. of three 
different experiments.*, p<0.05 when compared to OL-untreated cells.  
 
Figure 2. Differentiation of mitochondria upon osteogenic induction. (A) 
Representative western blots of the expression of mitochondrial proteins (NADHs9, 
NDUFS3, SDH-B, Core 2, COXI, COX II, COXIV, α-F1ATPase, β-F1ATPase, 
HADHA, Hsp60 and VDAC), glycolytic enzymes (GAPDH, PK-M2, and LDH-A) and 
tubulin in two different preparations of hMSCs and osteocytes. (B) hMSCs and 
osteocytes were processed for the determination of the relative mtDNA copy number 
(12S/β-F1-ATPase ratio). Bars represent the mean ± S.E.M. of seven independent 
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determinations. (C) The mitochondrial mass was determined by the content of 
cardiolipin as assessed by NAO fluorescence. Bars are the mean ± S.E.M of six 
independent determinations. *, p<0.05 when compared to hMSCs. (D) Fluorescence 
microscopy of hMSC and osteocytes stained with MitoTracker Red and Hoechst. 
Images reveal a partially fragmented mitochondrial network in hMSCs when compared 
to the thread-like morphology of mitochondria observed in osteocytes. The histogram 
shows the quantification of the MitoTracker signal in hMSCs and osteocytes. The 
results shown are the mean ± S.E.M of 45-60 different cells. a.u, arbitrary units. (E) 
Representative electron microscopy images of mitochondria in hMSCs and osteocytes. 
Onion-like mitochondria (white arrows) are observed in hMSCs. The histograms show 
the quantification of the number of mitochondria per cell section and the percentage of 
abnormal organelles in ultrathin sections of hMSCs and osteocytes, respectively. The 
results shown are the mean ± S.E.M of 45-50 different cells. *, p<0.05 when compared 
to hMSCs. (F) The histogram shows the mean ±S.E.M of the calculated β-F1-
ATPase/Hsp60 ratio in hMSCs and osteocytes in four different samples. *, p<0.05 when 
compared to hMSCs.  
 
Figure 3. IF1 degradation mediates metabolic reprogramming of stem cells during 
osteogenic differentiation. (A) Representative blots of IF1 and tubulin in two different 
preparations of hMSCs and osteocytes. Osteogenic induction is accompanied by 
repression of IF1 expression. (B-D, H) hMSCs were transfected with control (siCRL, 
closed bars) or siIF1 siRNA (siIF1, hatched bars) to regulate the expression of IF1. (B) 
Shows the rates of aerobic glycolysis in the absence (-) or presence (+) of 6 µM OL. 
Bars are the mean ± S.E.M. of 6 independent determinations. *, and #, p<0.05 when 
compared to siCRL or siIF1 untreated cells, respectively. (C) The rates of OL-sensitive 
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respiration (OSR) were determined after addition of 6 µM OL. Data are shown as 
percentage of the basal respiration. Bars are the mean ± S.E.M. of eight independent 
determinations. *, p<0.05 when compared to siCRL. (D) Cellular ATP concentrations 
were determined in the absence (-) or presence (+) of 6 µM OL. Bars are the mean ± 
S.E.M. of twelve independent determinations. *, p<0.05 when compared to OL-
untreated cells. (E) IF1 mRNA expression was assessed by RT-qPCR in hMSCs and 
osteocytes. Bars are the mean ± S.E.M. of six independent determinations. (F) hMSCs 
and osteocytes were treated twenty-four hours with (+) or without (-) 400µM of the 
serine-protease inhibitor AEBSF to block the activity of mitochondrial proteases, and 
the expression of IF1 and β-actin (loading control) analyzed by western blot in two 
different preparations. Plots are the mean ± S.E.M. of the calculated IF1/β-actin ratio in 
four different experiments.*, p<0.05 when compared to untreated (-) cells. (G) The rates 
of aerobic glycolysis in the absence (-) or presence (+) of 400µM of AEBSF or 6µM OL 
were determined in hMSCs and osteocytes. Bars are the mean ± S.E.M. of 6 
independent determinations.*, p<0.05 when compared to untreated cells. (H) The 
expression of CD44 and osteopontin was analyzed by western blot at the indicated times 
to asses the rate of differentiation after silencing of IF1. The plot represents the 
calculated osteopontin/CD44 ratio in siCRL and siIF1 cells. *, p<0.05 when compared 
to siCRL.  
 
Figure 4. IF1 is a stem cell marker. (A) Immunohistochemistry of IF1 expression in 
human normal and tumor prostate and colon tissues. Images are shown at 20-40X 
magnification (B) Double-immunofluorescence microscopy of normal human prostate 
and colon stained with CD44 antibody (green) and with monoclonal IF1 antibody (red). 
The merged images revealed the co-localization of IF1 in stem cells niches of both 
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tissues. Images are shown at 40X magnification. (C) Scheme of the proposed 
mechanism by which IF1 (dark blue) regulates metabolic rewiring upon cellular 
differentiation / dedifferentiation. Stem and cancer cells (dark yellow) show a high 
expression of IF1 which promotes the inhibition of OXPHOS favoring aerobic 
glycolysis. Differentiation triggers an enhanced degradation of IF1 (+, green) and the 
activation of OXPHOS in the differentiated cell (light blue). The relevance of glycolysis 
as ATP supplier is diminished in this situation. Dedifferentiation of somatic cells into 
cancer cells results in the accumulation of IF1, the inhibition of OXPHOS and the 
activation of aerobic glycolysis. The accumulation of IF1 in cancer cells might be 
regulated by inhibiting the degradation of the protein (-, red).  
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Figure S1. Oligomycin (OL) treatment has no effect on cell death in hMSCs and 
osteocytes. Cells were exposed to 6 μM OL or left untreated.  Cells were double-stained 
with Hoechst 33342 (green) and propidium iodide (PI, red) and visualized using 
fluorescence microscopy at 20x magnification. The percentage of PI positive cells (dead 
cells) was determined by examination of 10 different fields taken at random. 
Histograms are the means ± S.E.M.  
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Figure S2. Differentiation of mitochondria upon osteogenic induction. A. 
Histograms show the quantification of the expression of mitochondrial (NADHs9, 
NDUFS3, SDH-B, Core 2, COXI, COXII, COXIV, α-F1-ATPase, β-F1-ATPase, 
HADHA, Hsp60 and VDAC) and glycolytic (GAPDH, LDH-A and PK-M2) enzymes 
in hMSCs (closed bars) and osteocytes (open bars) (for representative blots see Fig. 
2A). The bioenergetic signature (β-F1/GAPDH ratio) in hMSCs and osteocytes is also 
shown. Data are expressed as fold change relative to the values in hMSCs. Bars 
represent the mean ± S.E.M. of four different preparations.*, p<0.05 when compared to 
hMSCs. B. Analysis of OXPHOS complexes by BN-PAGE in the presence of n-
dodecyl β-D-maltoside from digitonin-enriched mitochondrial membranes from hMSC 
and osteocytes (OST). A representative experiment is shown. The membrane has been 
sequentially blotted with antibodies against complex III (CIII), complex V (F0F1), 
complex IV (CIV), complex II (CII) and complex I (CI). The migration of F1-ATPase 
(F1), supercomplex I+III (SC I+III) and of molecular mass markers (kDa) is also 
indicated.  
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Figure S3. Post-transcriptional regulation of mitochondrial differentiation.  Total 
RNA was extracted from hMSC (closed bars) and osteocytes (open bars). (A) 
Expression of representative mitochondrial (β-F1-ATPase, Hsp60, COXIV, COXI, and 
SDH-B) and glycolytic (GAPDH, LDH-A and PK-M2) mRNAs was assessed by RT-
qPCR. Histograms show the mean ± S.E.M. of six different determinations. *, p<0.05 
when compared to hMSCs. (B) Quantification of miR-127-5p by RT-qPCR in hMSCs 
and osteocytes. RNU48 values are shown to highlight the negligible expression of miR-
127-5p in both undifferentiated and differentiated cells. Bars are the mean ± S.E.M. of 3 
independent determinations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. IF1 is not signaling cellular proliferation in hMSC.  hMSCs were 
transfected with control (siCRL, closed bars) or siIF1 siRNA (siIF1, hatched bars) to 
regulate the expression of IF1. Cellular proliferation was assessed by the incorporation 
of EdU into cellular DNA. Blue (Control, siCRL) and red (siIF1) traces are shown. Bars 
are the mean ± S.E.M. of 6 independent determinations. Data are shown as fold change 
relative to the values in siCRL cells.  
 
 
β-F1 Hsp60 COXI COXIV SDH-Bm
R
N
A
 e
xp
re
ss
io
n 
(fo
ld
 o
f h
M
SC
)
GAPDH LDH-A PK-M2
A
0.0
0.4
0.8
1.2 RNU48
hM
SC Os
t
m
iR
-1
27
-5
p 
 e
xp
re
ss
io
n
hM
SC Os
t
B
*
0
1
2
3
*
m
R
N
A
 e
xp
re
ss
io
n 
(fo
ld
 o
f h
M
SC
)
m
iR
-1
27
-5
p 
 e
xp
re
ss
io
n
m
iR
-1
27
-5
p 
 e
xp
re
ss
io
n
0
0.5
1.0
1.5
- +
C
el
lu
la
r p
ro
lif
er
at
io
n 
(fo
ld
 o
f s
iC
R
L)
: siIF1
-IF1 
-βF1 
siCRL siIF1
1 12 2
100 101 102 103 104
FL2-H
0
100
200
300
400
# 
C
el
ls
100 101 102 103 104
FL2-H
0
100
200
300
400
# 
C
el
ls
siCRL siIF1
100 101 102 103 104
FL2-H
0
20
40
60
80
100
%
 o
f M
ax
siCRL
siIF1
C
el
lu
la
r p
ro
lif
er
at
io
n 
(fo
ld
 o
f s
iC
R
L) # C
el
ls
# 
C
el
ls
%
 o
f M
ax
 
Figure S5. siRNA screening for the putative protease involved in the degradation 
of IF1. hMSCs (A) and HCT116 colon cancer cells (B) were transfected for 48 hours 
with 80-100 nM siCRL or with the specified siRNA for the following mitochondrial 
proteases: AFG3L2, CLPP, HtrA2, LONP1, PMPCB, SPG7 and YME1L1. 
Representative blots of IF1 and β-actin are shown. The calculated IF1/β-actin ratio is 
indicated on top of the blots. Silencing of CLPP, HtrA2 and LONP1 was verified by 
western blotting and the degree of silencing indicated on top of the blots. Silencing of 
AFG3L2, PMPCB, SPG7 and YME1L1 was verified by RT-qPCR and indicated.  
 
 
 
Supporting Methods 
Osteogenic induction and treatments. To induce osteogenic differentiation, hMSCs 
were incubated in the osteogenic media containing dexamethasone, ascorbate, 
Mesenchymal Cell Growth Supplement, L-glutamine, penicillin/streptomycin and β-
glycerophosphate (Lonza). For inhibition of mitochondrial serine-proteases, hMSC and 
osteocytes were treated with 400µM of 4-(2-aminoethyl) benzenosulfonyl fluoride 
hydrochloride (AEBSF) for the indicated time.  
Antibodies used: anti-CD44 (1:1,000) from Millipore; anti-β-F1-ATPase (1: 25,000) 
[1]; anti-IF1 (1:200) [2]; anti-PK-M2 (pyruvate kinase M2) (1:1000); anti-NADHs9 
(NADH dehydrogenase subunit 9) (1:1,000); anti-GAPDH (1:20,000); anti-LDH-A 
(1:1,1000) [3]; anti-Hsp60 (Heat Shock Protein) (Stressgene SPA-807, 1:2,000); anti-
SDH-B (succinate dehydrogenase subunit B) (1:500) and anti-COXIV (cytocrome c 
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oxidase subunit IV (1:250) from Invitrogen; anti-α-F1-ATPase (α-F1-ATPase) (1:1,000) 
from Molecular Probes; anti-osteopontin (1:1,000),  anti-NDUFS3 of complex I 
(1:1,000),  anti-Core 2 of complex III (1:500),  anti-MTCO2 (cytocrome c oxidase 
subunit II) (1:500), anti-MTCO1 (cytocrome c oxidase subunit I) (1:100), anti-VDAC1 
(porin) (1:500), anti-LONP1 antibody (1:250) and anti-CLPP (1:200) from Abcam; anti-
Htra2/Omi (1:500) from Cell Signaling; anti-tubulin (1:5,000) and anti-β-actin 
(1:100,000) from Sigma. Peroxidase-conjugated anti-mouse and anti-rabbit IgGs 
(Nordic Immunonology, 1: 3,000) were used as secondary antibodies.  The blots were 
developed using the ECL reagent. Quantification of the immunoreactive bands was 
accomplished using a Kodak DC120 Zoom digital camera and the Kodak 1D Image 
Analysis Software for Windows. The ratios β-F1-ATPase/Hsp60 and β-F1-
ATPase/GAPDH were taken as respective indexes of the bioenergetic competence of 
the organelle (mitochondrial differentiation) and of the overall mitochondrial activity in 
the cell (that results from both mitochondrial proliferation and differentiation), and 
illustrate the two main pathways that restrain the bioenergetic activity of mitochondria 
in cancer cells [1, 4].  
siRNA silencing. Transfections were performed using Lipofectamine and Plus Reagent 
(Invitrogen™). Suppression of IF1 (Qiagen S100908075) expression was exerted by 
small interfering RNA (siRNA). An inefficient siRNA sequence, Silencer® Select 
Negative Control #1 plasmid (Ambion/Applied Biosystems), was used as a control.  
Suppression of expression of mitocondrial proteases was exerted using the following 
Silencer Select siRNAs (Invitrogen): LONP1 (s17903), CLPP (s15686), HTRA2 (s653), 
AFG3L2 (s21516), SPG7 (s224671), PMPCB (s18239), YME1L1 (s21077). Silencer 
Negative Control siRNA #1 (AM4636) was used as control. Silencing was verified by 
western blotting (LONP1/CLPP/HTRA2) or by RT-qPCR 
(AFG3L2/SPG7/PMPCB/YME1L1). The forward (F) and reverse (R) primers used 
were: β-actin, F: 5’- CCAACCGCGAGAAGATGA-3’, R: 5’-
CCAGAGGCGTACAGGGATAG-3’;  PMPCB, F: 5’-
TGCCAGCTTGCTGTTTAATG-3’, R: 5’-TTGCCTCTTTTATGGAAATGG-3’; 
YME1L1, F: 5’-CATGGTGGCAGGTGCTTAT-3’, R: 5’-
CTCCATCTCCCAGGCTCA-3’; SPG7, F: 5’-GTCCGGCTTCTCCAACAC-3’, R: 5’-
AGGGTAGCTGGTCAAGAGAGG-3’; AFG3L2, F: 5’-
GAGGAAGAGGCAACTTTGGA-3’, R: 
5’AATGACGACATTTGTTGTTGTATTAAA-3’. 
Immunohistochemistry. Formalin-fixed, paraffin-embedded normal and tumor 5 μm 
sections of human colon and prostate biopsies were used (Origene). Sections were 
deparaffined and the antigens retrieved by incubation in EDTA for 45 min at 155ºC. 
The monoclonal anti-IF1 (1:200) antibody was used as detailed [5]. Sections were 
counterstained with hematoxylin.  
Immunofluorescence microscopy. For co-localization studies, deparaffinated normal 
human colon and prostate 5 μm tissue sections were used. The primary antibodies used 
were anti-CD44 (1:50) and anti-IF1 (1:50) [2]. Slides were incubated for 2h in the dark 
with anti-(rabbit) and anti-(mouse) IgGs conjugated to Alexa Fluor® 488 and 555, 
respectively. Cellular fluorescence was analyzed by confocal microscopy in a LSM510 
META (Zeiss). 
Gene expression analysis by RT-qPCR. Total RNA was extracted from cell cultures 
using TRIzol Reagent (Invitrogen) or RNAeasy Mini Kit (QIAgen). RNA was 
quantified with a Nanodrop ND-1000 spectrophotometer. RNA integrity was assessed 
with an Agilent 2100 Bioanalyzer. Reverse transcription (RT) reactions were performed 
using 1 µg of total RNA and the High Capacity Reverse Transcription Kit (Applied 
Biosystems) with random primers, following manufacturer’s instructions. Real-time 
PCR was performed using Power Sybr Green PCR Master Mix with an ABIPRISM 
7900HT instrument (Applied Biosystems). The expression level of indicated mRNAs 
was determined according to the ΔΔCt method using β-actin as internal control. 
Assessment of cellular proliferation. The incorporation of 5-ethynyl-2´deoxy-uridine 
(EdU) into cellular DNA was determined using the Click-iT EdU Flow Cytometry 
Assay Kit (Molecular Probes) [5].  
Cell death assays. Cells were harvested, washed with PBS and incubated in the dark 
for 5 min with Hoechst 33342 (1mg/mL) and propidium iodide (1mg/mL) solutions. 
After washing, samples were observed under a Leica DM-IRB fluorescence microscope 
(UV). The percentage of dead (red staining) cells was calculated from 10 different 
randomly selected fields for each condition assayed. 
Blue native electrophoresis (BN)-PAGE. Enriched mitochondrial fractions were 
isolated from cell cultures using digitonin [6]. Protein extracts were solubilized in BN-
loading buffer (1.5 M 6-aminocaproic acid, 50 mM Bis-Tris/HCl pH 7.0) in the 
presence of 2 μl PMSF/0.5 mM DMSO. n-dodecyl β-D-maltoside at the concentration 
of 3 g/g protein was added to the samples and incubated on ice for 10 min. Solubilized 
samples were centrifuged for 30 min at 30,000 rpm at 4ºC, and the supernatant was 
combined with 2 μl of sample buffer (500 mM aminocaproic acid, 50 mM Bis-Tris/HCl 
pH 7.0, 0.5 mM EDTA, 5% Serva Blue G-250) prior to loading in 3-13% gradient gels 
[7].  
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